Preliminary blinded CR rate showed 67% improvement over historical cytarabine responseRoughly 35% of the subjects treated to date represent ...
11h
Moleculin Biotech, Inc.: Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)
Preliminary blinded CR rate showed 67% improvement over historical cytarabine response Roughly 35% of the subjects treated to date represent ventoclax regimen failuresFirst 45 subjects treated on trac ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results